Table of Contents - Part 1 of 2
- A word from the editor
- Introduction
- Adjuvant Chemoradiation
- Bolus vs Infusional Fluorouracil(Drug information on fluorouracil)
- Adjuvant Chemotherapy
- Ongoing Clinical Trials
- Conclusions
- References
- Part 2 of 2
Activity Release Date: May 1, 2009
Activity Expiration Date: May 1, 2010
About the Activity
This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.
Activity Learning Objectives
After reading this article, participants should be able to:
- Assess the use of postoperative adjuvant chemotherapy following chemoradiation
- Appraise new and novel preoperative chemoradiation regimens
- Appraise the role of local excision in the surgical management of rectal cancer
- Demonstrate knowledge of the role of available types of radiation therapy - convention, 3D, and IMRT
Target Audience
This activity targets physicians in the fields of oncology and hematology.
Accreditation
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Continuing Education Credit
AMA PRA Category 1 Credit™
CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Compliance Statement
This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
However, CME LLC, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.
Financial Disclosures
Dr. Minsky serves as a consultant and is on the speakers bureau for sanofi-aventis U.S., Genentech, Inc., and Bristol-Myers Squibb Company.
Dr. Chu serves as a consultant for F. Hoffmann-La Roche Ltd, ImClone Systems Incorporated, and Merck-Serono.
Copyright
Copyright owned by CME LLC. Copyright 2009, all rights reserved.
Contact Information
We would like to hear your comments regarding this or other activities provided by CME LLC. In addition, suggestions for future activities are welcome. Contact us at:
Director of Continuing Education
CME LLC
Harborside Financial Center, Plaza 3, Suite #806
Jersey City, NJ 07311
Phone: 800-447-4474
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
